Focus: Cinclus Pharma is a Swedish public pharmaceutical company focused on GERD treatment and gastroenterology. The company operates with a focused pipeline centered on innovative acid reflux therapies.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cinclus Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cinclus Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cinclus Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Cinclus Pharma Ramps Up Investor Outreach Ahead of Late-Stage GERD Drug Push - TipRanks
Cinclus Pharma Ramps Up Investor Outreach Ahead of Late-Stage GERD Drug Push TipRanks
Cinclus Pharma to participate in upcoming investor conferences - Finansavisen
Cinclus Pharma to participate in upcoming investor conferences Finansavisen
Claret Capital Partners invests €28M in Cinclus Pharma - GlobeNewswire
Claret Capital Partners invests €28M in Cinclus Pharma GlobeNewswire
Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US – Positive for the Company’s Phase III Program - Finansavisen
Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US – Positive for the Company’s Phase III Program Finansavisen
Year-end report – Advancing toward Phase III readout - Finansavisen
Year-end report – Advancing toward Phase III readout Finansavisen
Cinclus Pharma receives regulatory support – EMA provides positive feedback on CMC for linaprazan glurate - Finansavisen
Cinclus Pharma receives regulatory support – EMA provides positive feedback on CMC for linaprazan glurate Finansavisen
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company